Last reviewed · How we verify

Calcipotriol BDP gel

LEO Pharma · Phase 3 active Small molecule

Calcipotriol is a vitamin D3 analog that binds to the vitamin D receptor to regulate skin cell differentiation and reduce inflammation in psoriasis.

Calcipotriol is a vitamin D3 analog that binds to the vitamin D receptor to regulate skin cell differentiation and reduce inflammation in psoriasis. Used for Plaque psoriasis (topical treatment).

At a glance

Generic nameCalcipotriol BDP gel
SponsorLEO Pharma
Drug classVitamin D3 analog / Corticosteroid combination
TargetVitamin D receptor (VDR); Glucocorticoid receptor
ModalitySmall molecule
Therapeutic areaDermatology
PhasePhase 3

Mechanism of action

Calcipotriol activates the vitamin D receptor on keratinocytes and immune cells, promoting normal differentiation of skin cells and suppressing the inflammatory T-cell response characteristic of psoriasis. BDP (betamethasone dipropionate) is a potent corticosteroid that provides additional anti-inflammatory effects. The combination gel formulation delivers both agents topically to affected skin.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: